Valuation : Lineage Cell Therapeutics, Inc.

Market Cap 255M 220M 208M 189M 354M 24.4B 356M 2.48B 952M 12.42B 959M 938M 39.23B P/E 2026 *
-15x
P/E 2027 * -9.68x
Enterprise Value 255M 220M 208M 189M 354M 24.4B 356M 2.48B 952M 12.42B 959M 938M 39.23B EV / Sales 2026 *
16.8x
EV / Sales 2027 * 15.2x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day-0.98%
1 week-6.48%
Current month-8.18%
1 month-9.82%
3 months-21.09%
6 months-39.88%
Current year-39.52%
1 week 1
Extreme 1
1.16
1 month 1
Extreme 1
1.18
Current year 1
Extreme 1
1.98
1 year 1
Extreme 1
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.71
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Free

Director

125,000 0.0501%
7/1/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
7/1/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%-6.48%-21.71%-24.06% 258M
-0.71%-6.35%-4.87%+9.03% 46.05B
+0.21%-2.98%+340.68%+519.93% 43.59B
+1.74%-2.24%+37.28%+21.57% 42.35B
+1.38%-3.28%+3.23%+65.60% 38.86B
-1.44%-5.26%+8.78%+36.85% 32.24B
+0.87%-2.60% - - 17.16B
+0.75%-0.64%+18.07%+110.32% 16.28B
-0.31%-2.78%+10.47%+30.49% 14.32B
+1.93%-3.55%+74.20%+39.37% 13.03B
Average +0.34%-4.53%+51.79%+89.90% 26.41B
Weighted average by Cap. +0.40%-4.51%+72.95%+123.36%

Financials

2026 *2027 *
Net sales 15.19M 13.09M 12.39M 11.23M 21.08M 1.45B 21.18M 147M 56.61M 738M 57.06M 55.81M 2.33B 16.83M 14.5M 13.73M 12.45M 23.35M 1.61B 23.47M 163M 62.73M 818M 63.22M 61.84M 2.59B
Net income -22.64M -19.51M -18.47M -16.74M -31.41M -2.16B -31.57M -219M -84.36M -1.1B -85.03M -83.16M -3.48B -34.44M -29.67M -28.1M -25.47M -47.78M -3.29B -48.02M -334M -128M -1.67B -129M -127M -5.29B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
26-09-11 $1.010 -0.98% 910,397
26-09-10 $1.020 -0.97% 1,197,740
26-09-09 $1.030 -5.50% 1,364,316
26-09-08 $1.090 +0.93% 1,312,122
26-09-04 $1.080 -1.82% 535,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.010USD
Average target price
5.500USD
Spread / Average Target
+444.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!